Quest Diagnostics stock edges lower near 52-week highs after solid Q2 growth
Published on 09/07/2026 at 15:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics Incorporated (ISIN US74834L1008) stock is quoted around USD 237.14 as of September 6, 2026, leaving the New Jersey-based diagnostics group just below recent 52-week highs near USD 246 after a modest daily decline of about 0.94 percent.Pluang The valuation of roughly USD 26.17 billion underlines that investors continue to price in robust growth following strong second-quarter figures for 2026.Pluang
Q2 2026 results show double-digit growth
For the quarter ended June 2026, Quest Diagnostics reported revenues of USD 3.04 billion, representing a year-over-year increase of 10.2 percent according to Zacks data.Zacks In the same period, diluted earnings per share reached USD 3.12, up from USD 2.62 a year earlier, which corresponds to earnings growth of roughly 19.1 percent and signals improving profitability on higher test volumes and mix.Zacks The combination of double-digit top-line growth and a nearly one-fifth increase in earnings per share positions the Q2 2026 report as a key fundamental driver behind the current valuation.
Analysts tracked by Zacks expect Quest Diagnostics to earn USD 2.85 per share in the current quarter, implying a projected year-over-year increase of 9.6 percent.Zacks Over the last 30 days, the Zacks Consensus Estimate has inched up by 0.1 percent, a small but positive revision that suggests expectations remain broadly stable after the Q2 beat.Zacks From an investor perspective, this guidance-like consensus trend indicates that the market is looking for continued, albeit slightly slower, earnings growth in the second half of 2026.
Stock holds up despite Labor Day trading pause
On September 7, 2026, US equity markets including the New York Stock Exchange and Nasdaq are closed for the Labor Day holiday, meaning Quest Diagnostics stock is not trading on that date.TradingKey According to TradingKey, regular trading will resume on September 8, 2026, with standard hours, so the latest available quote of USD 237.14 and the reported 0.94 percent daily decline refer to the last completed session before the holiday, namely September 6, 2026.PluangTradingKey This context is important for short-term traders, as intraday price moves on September 7, 2026, are absent due to the market closure.
The current price level leaves Quest Diagnostics stock within striking distance of its recent 52-week highs near USD 246, as noted by market data from Pluang.Pluang Put differently, the share price is only around USD 9 below that high watermark, which corresponds to a discount of about 3.7 percent relative to the recent peak. For investors, this proximity to the 52-week high can be interpreted as a sign that the market continues to reward the company’s earnings trajectory, while also limiting the immediate upside unless new catalysts emerge.
Analyst stance and risk considerations
According to Zacks, Quest Diagnostics currently carries a Zacks Rank #3 (Hold), which reflects a neutral stance based on the overall direction and magnitude of estimate revisions over the past month.Zacks The stock also has a VGM score of B, indicating relatively attractive value, growth and momentum characteristics in combination rather than in isolation.Zacks This mix of a Hold rating with favorable factor scores suggests that the analyst community sees the shares as reasonably valued after the recent run-up, with upside potential tied to execution on growth and margin expansion.
One risk factor for Quest Diagnostics stock in this environment is the competitive and regulatory landscape around diagnostic testing and laboratory services, which can pressure pricing and reimbursement levels over time. While the Q2 2026 numbers show clear year-over-year progress, sustained double-digit revenue growth and high-teens earnings expansion will depend on continued volume gains, efficient operations and stable reimbursement. Any slowdown in these areas or adverse policy changes could challenge the current consensus expectation of 9.6 percent earnings growth in the current quarter.Zacks For long-term shareholders, monitoring how actual results track relative to these expectations will be critical.
Operational momentum supported by new partnerships
Beyond the headline numbers, Quest Diagnostics is also active in expanding its service offerings through partnerships. An 8-K filing indicates that Insight Molecular Diagnostics Inc. entered into a specimen collection agreement with Quest Diagnostics on February 20, 2026, under which Quest provides specimen collection-related services for samples used in Insight’s GraftAssureCore blood test.StockTitan The GraftAssureCore test measures donor-derived cell-free DNA using a PCR-based platform, and Quest’s role as a collection partner underscores its positioning as an infrastructure provider in advanced diagnostics workflows.StockTitan
Financial details of the agreement are not fully disclosed in the snippet, but the filing notes that fees will be paid to Quest Diagnostics for the services provided and that both parties intend to negotiate additional rights related to the GraftAssure technology over a specified period.StockTitan Strategically, such collaborations can help Quest Diagnostics diversify its revenue base beyond routine testing, tapping into specialized assays that may carry higher value per sample. While the Q2 2026 revenue and EPS figures are not broken down by contribution from this partnership, investors can view agreements like these as part of the broader operational momentum supporting the company’s growth profile.
Representative product and segment context
A representative focus area for Quest Diagnostics is its comprehensive diagnostic testing services across clinical laboratory and enterprise analytics, which collectively generated the USD 3.04 billion revenue reported for Q2 2026.Zacks Within that total, core clinical testing, screening and health system support remain the backbone of the business model, providing recurring demand that tends to be less volatile than purely elective procedures. By combining scale in routine diagnostics with selective exposure to advanced tests such as the GraftAssureCore collaboration, Quest aims to balance stability and growth in its portfolio.StockTitan
Stock valuation and price snapshot
As of the last completed trading day before Labor Day, namely September 6, 2026, Quest Diagnostics stock traded at USD 237.14 on its primary US exchange, with the quote reflecting a 0.94 percent decline on that day.Pluang With a market capitalization reported at approximately USD 26.17 billion as of the same date, the shares remain firmly positioned among large-cap US healthcare names.Pluang For investors evaluating entry or exit points, the combination of a price close to the recent 52-week high and double-digit earnings growth suggests that the stock is priced for continued execution rather than for a turnaround scenario.
Quest Diagnostics stock at a glance
- Company: Quest Diagnostics Incorporated
- ISIN: US74834L1008
- Ticker: DGX
- Trading venue: NYSE
- Price (as of September 6, 2026): 237.14 USD
- Market capitalization: 26.17 billion USD (as of September 6, 2026)
- Sector / Industry: Health Care / Diagnostics & Research
- Index membership: S&P 500
